Brain Blood Flow Responses to Stress: Sex Differences
NCT06253702
Completed
Twenty-six otherwise healthy adults between 18-40 years of age composed of 13 males and 13 females will be enrolled in this study to determine how sex and sex hormones influence cerebral blood flow (CBF) control in healthy young adults without confounds of age or disease. Participants can expect to be on study for approximately 16 days.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
07/17/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Cerebrovascular Disorders
Register for Updates
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
NCT03570827
Completed
This phase II trial studies how well hypofractionated radiation therapy works in treating participants with prostate cancer high-risk features following radical prostatectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +1 locations
Conditions: Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Register for Updates
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT04363164
Recruiting
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.
Gender:
MALE
Ages:
Between 18 years and 90 years
Trial Updated:
07/10/2025
Locations: University of California, San Diego (UCSD), San Diego, California +5 locations
Conditions: Castration Resistant Metastatic Prostate Cancer
Register for Updates
52 Week Study of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
NCT06689085
Recruiting
This is a 52-week open label single arm study to investigate the effects of XYOSTED, as testosterone replacement therapy, on adolescent males with either primary or secondary hypogonadism. The study aims to determine the effectiveness of XYOSTED measured by continuation or induction of puberty in addition to XYOSTED dosage, safety and testosterone levels.
Gender:
MALE
Ages:
Between 12 years and 17 years
Trial Updated:
07/09/2025
Locations: Children's Hospital Colorado, Aurora, Colorado +7 locations
Conditions: Hypogonadism, Male
Register for Updates
Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging
NCT07069465
Completed
This is a pilot, non-randomized, two-cohort interventional study in patients who meet the inclusion criteria, using an FDA- approved androgen deprivation agent for a 3 or 6-week course of treatment prior to standard-of-care RALP with PLND. The intent of the study is to determine the effect of ADT on PSMA expression as measured by PSMA-PET scan. A second PSMA-PET scan will be performed after ADT for either 3 or 6 weeks, depending on cohort, prior to RALP and PLND.
Gender:
MALE
Ages:
All
Trial Updated:
07/07/2025
Locations: Urology Clinics of North Texas, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
NCT05011383
Recruiting
This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado +16 locations
Conditions: Metastatic Prostate Cancer
Register for Updates
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
NCT01409200
Active Not Recruiting
This randomized phase IIA trial studies how well antiandrogen therapy works with or without axitinib before surgery in treating patients with previously untreated prostate cancer that is known or suspected to have spread to lymph nodes. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as antiandrogen therapy may lessen the amount of androgen made by the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It i... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
Register for Updates
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
NCT04798469
Recruiting
The aim of this trial is to evaluate whether testosterone replacement results in greater improvement in pain perception, pain tolerance, sexual function, fatigue, and quality of life when compared with placebo in men with chronic spinal pain treated with opioids who have opioid-induced hypogonadism (low testosterone).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Opioid Use, Pain, Hypogonadism, Male
Register for Updates
The COSMYC Trial (COmbined Suppression of MYC)
NCT06922318
Not Yet Recruiting
This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigators also want to determine if dosing first with the combination of testosterone and ZEN-3694 may cause enzalutamide and ZEN-3694 to work more effectively.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
NCT06392295
Recruiting
The purpose of this prostate cancer research study is to learn about: 1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy; 2. Preserving quality of life after radiation therapy; 3. Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scans to evaluate and manage disease progression.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: University of Miami, Miami, Florida
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer
Register for Updates
Effectiveness of Qualia Testosterone Supplementation on Testosterone Levels
NCT07028255
Not Yet Recruiting
This is a randomized, double-blind, placebo-controlled parallel trial designed to assess the efficacy of Qualia Testosterone, a novel dietary supplement, in adult males aged 28 to 65 experiencing symptoms associated with testosterone deficiency. Approximately 60 participants will be randomized to receive either Qualia Testosterone (2 capsules daily) or a matched placebo for 21 days, with dosing administered each morning. The study's primary outcomes are changes in total testosterone, free testos... Read More
Gender:
MALE
Ages:
Between 28 years and 65 years
Trial Updated:
06/11/2025
Locations: Qualia Life Sciences, Carlsbad, California
Conditions: Testosterone
Register for Updates
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
NCT06205316
Recruiting
This phase III trial tests the side effects of stereotactic body radiation therapy (SBRT) compared to hypofractionated radiotherapy for treating patients with prostate adenocarcinoma that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to a limited number of sites (oligometastatic). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the bo... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +5 locations
Conditions: Biochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Register for Updates